Forensic · ESPR
Esperion Therapeutics
Top signals
Officer Departure Recent
C-suite officer departure (Item 5.02) in the last 6 months.
+4
Bear case preview · free
Esperion Therapeutics triggered a low-risk signal primarily on recent officer departure, suggesting potential internal instability at the C-suite level that could affect operational continuity or strategic direction. While a single departure doesn't constitute a material distress indicator, departures during critical product commercialization phases warrant scrutiny, particularly for smaller biotech firms with limited executive bench strength. Monitor the next 30-90 days for additional C-suite turnover, changes in guidance or clinical trial timelines, and any commentary on succession planning in upcoming filings.
↑ That's free. The $9 report goes deeper: every filing cited by accession number, 36-month chronology, what to watch next.
What we checked
✓ Red flags · 36mo
1 8-K event (bankruptcy, delisting, restatement, auditor, officer)
✓ Cyber · 12mo
0 Item 1.05 disclosures + buried-cyber scan
✓ Dilution · 24mo
0 S-3 + 424B5 filings
✓ Buried events
Item 8.01 sections classified for hidden material disclosures
$9
· one-time · emailed in under a minute
The full bear case on ESPR
Plain-English brief. Every signal cited to the exact SEC filing. 36-month chronology. What changes next.
✓ No-signals refund: if the algorithm finds zero red flags on your ticker, reply "refund" and I send the $9 back same day. No questions.
Not ready to buy? Get a free preview by email instead
We'll email you the top 3 signals on ESPR + a discount code for the full report. No subscription, no spam.
Score another ticker
Not investment advice. Every signal grounded in a specific SEC filing. Companies may respond via info@filingfirehose.com.